Kenvue Inc. $KVUE Stake Cut by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. cut its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 14.7% in the third quarter, HoldingsChannel reports. The fund owned 252,166 shares of the company’s stock after selling 43,368 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Kenvue were worth $4,093,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Salomon & Ludwin LLC purchased a new stake in shares of Kenvue in the third quarter worth approximately $25,000. NBT Bank N A NY increased its stake in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after buying an additional 1,006 shares during the period. Cornerstone Planning Group LLC lifted its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares in the last quarter. Golden State Wealth Management LLC lifted its position in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares in the last quarter. Finally, Trust Co. of Vermont boosted its stake in shares of Kenvue by 50.9% during the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after buying an additional 804 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Jeffrey C. Smith purchased 3,200,000 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were bought at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. This trade represents a 13.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.68% of the stock is currently owned by company insiders.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $18.50 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock has a market capitalization of $35.44 billion, a P/E ratio of 24.67 and a beta of 0.59. The business has a 50-day moving average of $17.32 and a two-hundred day moving average of $17.78. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.5%. Kenvue’s dividend payout ratio is presently 110.67%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Barclays upped their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Evercore set a $18.00 target price on Kenvue in a research report on Tuesday, October 28th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $15.00 price target (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Finally, Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Four research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $19.46.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.